Skip to main content

Peer Review reports

From: Clinical activity and safety of sintilimab, bevacizumab, and TMZ in patients with recurrent glioblastoma

Original Submission
1 Nov 2023 Submitted Original manuscript
12 Nov 2023 Reviewed Reviewer Report
25 Nov 2023 Reviewed Reviewer Report - Juan Manuel Sepúlveda Sánchez
1 Jan 2024 Author responded Author comments - Yujing Tan
Resubmission - Version 2
1 Jan 2024 Submitted Manuscript version 2
3 Jan 2024 Author responded Author comments - Yujing Tan
Resubmission - Version 3
3 Jan 2024 Submitted Manuscript version 3
Publishing
5 Jan 2024 Editorially accepted
25 Jan 2024 Article published 10.1186/s12885-024-11848-z

You can find further information about peer review here.

Back to article page